Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.
This study developed and validated a novel analytical strategy for characterizing how BPC-157 — a peptide classified as a doping agent — is metabolized in laboratory (in vitro) conditions. The researchers used stable isotope labeling (¹³C/¹⁵N-labeled BPC-157) combined with ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS) to systematically identify metabolites without needing prior knowledge of metabolic pathways. Using two in vitro incubation models, the study identified nine total metabolites: eight arising from conventional amide-bond cleavage and one from a previously unreported metabolic pathway. The team then developed and validated a detection method for BPC-157 and five key metabolites in human urine, achieving detection limits of 0.01–0.11 ng/mL and strong quantitative performance. Importantly, this was an entirely in vitro study; no human participants or animals were involved, meaning the metabolic profile observed may not fully reflect what occurs in the human body. The findings are primarily relevant to anti-doping laboratories seeking improved detection targets and analytical workflows, and do not speak to the biological effects or clinical utility of BPC-157.
Why this grade: The entire study was conducted using in vitro incubation models and analytical chemistry methods with no human participants or animal subjects, limiting direct extrapolation to in vivo human metabolism.
Traditional strategies for the metabolic profiling of doping are limited by the unpredictable metabolic pathways and the numerous proportions of background and chemical noise that lead to inadequate metabolism knowledge, thereby affecting the selection of optimal detection targets. Thus, a stable isotope labeling-based nontargeted strategy combined with ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) was first proposed for the effective and rapid metabolism analysis of small-molecule doping agents and demonstrated via its application to a novel doping BPC-157. Using 13 C/ 15 N-labeled BPC-157, a complete workflow including automatic 13 C 0 , 15 N 0 - 13 C 6 , 15 N 2 m / z pair picking based on the characteristic behaviors of isotope pairs was constructed, and one metabolite produced by a novel metabolic pathway plus eight metabolites produced by the conventional amide-bond breaking metabolic pathway were successfully discovered from two incubation models. Furthermore, a specific method for the detection of BPC-157 and the five main metabolites in human urine was developed and validated with satisfactory detection limits (0.01~0.11 ng/mL) and excellent quantitative ability (linearity: 0.02~50 ng/mL with R 2 > 0.999; relative error (RE)% 90%). The novel metabolic pathway and the in vitro metabolic profile could provide new insights into the biotransformation of BPC-157 and improved targets for doping control.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.